His-Tag Detection ELISA Kit

Recombinant proteins are routinely labeled with affinity tags, such as hexahistidine (6X-His), GST and FLAG, to facilitate both their detection and purification. 6X-His tags are often the tag of choice due to their small size, less potential to interfere in protein folding, weak immunogenicity, and high affinity for Ni²⁺. Cell lysates and samples at different stages of purification are generally analyzed by SDS-PAGE, a process which can add several days to the purification and analysis protocol. A semi-quantitative screening assay provides the ability to rapidly assess the levels His-tagged proteins at each stage of the expression and purification process. This permits the user to quickly monitor expression efforts, as well as follow protein loss or enrichment at each purification step. Cayman’s His-Tag Detection ELISA Kit is competitive assay designed for the rapid, semi-quantitative screening of cell lysates and affinity column fractions for His-tagged proteins. It is intended to serve as a substitute for SDS-PAGE, thereby expediting the screening of affinity column fractions.

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.

Taha, Z., Crupi, M.J.F., Alluqmani, N., et al. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy. Nat. Commun. 15(1), 7267 (2024).

Hwang, Y.E., Im, S., Cho, J.H., et al. Semi-biosynthetic production of surface-binding adhesive antimicrobial peptides using intein-mediated protein ligation. Int. J. Mol. Sci. 23(23), 15202 (2022).

Chen, J., Peng, J., Ma, C., et al. Co-expression of pig IL-2 and fusion bovine cathelicidin gene by recombinant plasmids in yeast and their promotion of mouse antibacterial defense. Biology (Basel) 11(10), 1491 (2022).

Crupi, M.J.F., Taha, Z., Janssen, T.J.A., et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front. Immunol. 13, 1029269 (2022).